Fraud Investigation: Levi & Korsinsky Investigates Immutep Limited (IMMP) on Behalf of Shareholders

Core Viewpoint - Immutep Limited is under investigation for potential violations of federal securities laws following a significant drop in share price due to negative results from a clinical trial analysis [1][3]. Group 1: Company Developments - On January 30, 2026, Immutep filed a 6-K with the SEC indicating that the TACTI-004 futility analysis was "on track for the first quarter of CY2026" and highlighted "strong operational progress" for the trial [2]. - The interim futility analysis announced on March 13, 2026, indicated that the drug was unlikely to succeed, leading to a recommendation to stop the study [2][3]. - The discrepancy between the positive guidance in January and the negative outcome in March resulted in a share price decline of up to 90% in a single session [3]. Group 2: Legal and Financial Implications - Levi & Korsinsky has initiated an investigation into Immutep Limited for potential recovery options for investors who suffered losses on their securities [1][4]. - The firm has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5].